Apricity Health generates longitudinal ePRO, EHR, and genomic data from diverse patient populations to augment routine cancer care. This real-world patient data informs drug developers on the efficacy and failure points of current standard of care treatments. The company uses these human insights to drive the development of precision therapeutics tailored for individual patients.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatment and drug development processes are often reactive and disconnected from real-world patient outcomes. This disconnect leads to a significant portion of patients not benefiting from existing therapies and limits the identification of novel therapeutic targets.
Solution
Apricity Health empowers drug developers by leveraging patient data to identify treatment failures and discover new therapeutic opportunities. The platform facilitates the development of precision therapeutics informed by real-world insights and grounded in scientific expertise. By analyzing longitudinal data from diverse patient populations, Apricity Health aims to enhance patient care and personalize treatment strategies. This approach enables a more proactive and data-driven methodology in oncology drug discovery and development.
Target Audience
Apricity Health targets pharmaceutical and biotechnology companies engaged in oncology drug discovery and development.
Features
- Data aggregation platform for longitudinal ePRO, EHR, and genomic data.
- Machine learning models to analyze treatment efficacy and identify patient subgroups.
- Predictive analytics for understanding drug failure mechanisms.
- Identification of novel therapeutic targets based on real-world evidence.
- Tools for dynamic patient selection in clinical trial design.
- Integration capabilities with existing healthcare data systems.